Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $20.5 million.

  • Bioventus' Other Non-Current Liabilities fell 2172.42% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year decrease of 2172.42%. This contributed to the annual value of $23.1 million for FY2024, which is 1729.79% down from last year.
  • Per Bioventus' latest filing, its Other Non-Current Liabilities stood at $20.5 million for Q3 2025, which was down 2172.42% from $21.3 million recorded in Q2 2025.
  • Over the past 5 years, Bioventus' Other Non-Current Liabilities peaked at $81.9 million during Q4 2022, and registered a low of $20.5 million during Q3 2025.
  • Its 5-year average for Other Non-Current Liabilities is $29.0 million, with a median of $26.9 million in 2024.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 16504.24% in 2022, then plummeted by 6226.29% in 2023.
  • Bioventus' Other Non-Current Liabilities (Quarter) stood at $21.7 million in 2021, then increased by 5.0% to $22.8 million in 2022, then rose by 22.46% to $27.9 million in 2023, then dropped by 17.3% to $23.1 million in 2024, then fell by 11.41% to $20.5 million in 2025.
  • Its last three reported values are $20.5 million in Q3 2025, $21.3 million for Q2 2025, and $22.0 million during Q1 2025.